GeneCentric was founded based on intellectual property from Drs. Neil Hayes and Chuck Perou’s laboratories at the Lineberger Comprehensive Cancer Center at the UNC School of Medicine.
GeneCentric currently has two unique platform technologies: The Lung Subtype Platform (LSP™) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP™ was licensed to and independently developed by Laboratory Corporation of America® Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. GeneCentric’s second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies.
GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. By partnering with the foremost clinical laboratories, in-vitro diagnostic (IVD), pharmaceutical, and biotech companies, GeneCentric can focus on its core strength, exceptional science and clinical studies, building evidence for the utility of its unique assays.
GeneCentric currently has two unique platform technologies: The Lung Subtype Platform (LSP™) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP™ was licensed to and independently developed by Laboratory Corporation of America® Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. GeneCentric’s second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies.
GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. By partnering with the foremost clinical laboratories, in-vitro diagnostic (IVD), pharmaceutical, and biotech companies, GeneCentric can focus on its core strength, exceptional science and clinical studies, building evidence for the utility of its unique assays.
Employees: 11-50
Total raised: $8M
Founded date: 2011
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.06.2025 | Series C | $8M | - |
Mentions in press and media 14
| Date | Title | Description |
| 20.06.2025 | The Surge of Precision Medicine: A New Era in Cancer Diagnostics | In the world of healthcare, precision medicine is the lighthouse guiding us through the fog. It promises tailored treatments, turning the tide against diseases like cancer. Recent funding rounds for companies like PreciseDx and GeneCentric ... |
| 18.06.2025 | GeneCentric Therapeutics Holds Initial Closing of $8.0M Series C Financing | GeneCentric Therapeutics, a Durham, NC-based company advancing precision medicine through gene expression, announced the initial closing of an $8.0m Series C financing. The round was led by Hatteras Venture Partners, with current participat... |
| 08.11.2021 | GeneCentric Therapeutics Closes $7.5 Million Series B1 Financing | GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced the closing of an oversubscribed Series B1 financing, which raised $7.5 million. Proceeds will be used to commercializ... |
| 08.11.2021 | GeneCentric Therapeutics Closes $7.5M Series B1 | DURHAM, NC, GeneCentric Therapeutics, an RNA-based diagnostics startup, raised $7.5 million Series B1 financing. >> Click here for more funding data on GeneCentric Therapeutics >> To export GeneCentric Therapeutics funding d... |
| 15.08.2019 | GeneCentric Therapeutics Buys Select ImmunoGenomics | GeneCentric Therapeutics, Inc., a Research Triangle Park, N.C.-based RNA-based genomic solutions provider, acquired Select ImmunoGenomics, LLC, a Chapel Hill, NC-based provider of advanced immunogenomic, data analysis and biomarker developm... |
| 05.01.2017 | Durham-based GeneCentric Diagnostics Raises $6.1 Million | GeneCentric Diagnostics Inc. filed Thursday to raise over $8.6 million in equity, according to a filing with the Securities and Exchange Commission. The company has already raised more than $6.1 million through four investors with almost $2... |
| 05.01.2017 | Durham-based GeneCentric Diagnostics Raises $6.1 Million | GeneCentric Diagnostics Inc. filed Thursday to raise over $8.6 million in equity, according to a filing with the Securities and Exchange Commission. The company has already raised more than $6.1 million through four investors with almost $2... |
| 30.04.2014 | Investors wager $47M more on a blood test to curtail unnecessary lung biopsies and surgeries | It’s usually caught when lung nodules – small, oval-shaped growths in the lungs – appear in chest X-rays or CT scans. Most of the time, lung nodules are benign, especially if they’re very small. But a variety of factors including a person’s... |
| 08.07.2013 | Molecular diagnostics company GeneCentric collects $2.5 million for cancer tests | A second platform, a 13-gene hypoxia signature, is under development to identify cancer patients who may respond to anti-angiogenesis inhibitors. The advent of whole genome sequencing has driven many diagnostics companies to use gene signat... |
| 20.09.2011 | Cancer diagnostics firm GeneCentric raises $250,000 | Perou and Hayes are already working together on genomic cancer research. The two are leading a team of UNC researchers supported by a Cancer Genome Atlas Grant. In August, UNC was named as one of 12 research centers participating in the eff... |
Show more